ImmuCell Corp. of Portland, Maine, said Tuesday it signed alicense and supply agreement with Univax Biologics Inc. ofRockville, Md., covering ImmuCell's antibody-based therapeuticto treat cryptosporidiosis in AIDS patients.
Under the agreement, ImmuCell is eligible for $2 million inresearch support and milestone payments from Univax duringthe next three years and retained exclusive manufacturingrights to the product. The deal should "put ImmuCell near abreak-even operating level" for the last nine months of 1992,said Michael F. Brigham, the company's chief financial officer.
ImmuCell's passive antibody technology for this application hasreceived Orphan Drug designation and is now in Phase I clinicaltrials.
(c) 1997 American Health Consultants. All rights reserved.